A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
C Fernández-Miranda, M Pérez-Carreras… - Digestive and Liver …, 2008 - Elsevier
BACKGROUND: Dyslipidaemia and insulin resistance are two important risk factors for non-
alcoholic fatty liver disease. Both factors can improve with fenofibrate. AIMS: To evaluate the
effect of fenofibrate on the clinical, analytical and histological evolution of patients with non-
alcoholic fatty liver disease. SUBJECTS AND METHODS: Sixteen consecutive patients with
biopsy-confirmed non-alcoholic fatty liver disease were treated with 200mg/day of
fenofibrate for 48 weeks. A clinical and biochemical follow-up was done every 3 months. A …
alcoholic fatty liver disease. Both factors can improve with fenofibrate. AIMS: To evaluate the
effect of fenofibrate on the clinical, analytical and histological evolution of patients with non-
alcoholic fatty liver disease. SUBJECTS AND METHODS: Sixteen consecutive patients with
biopsy-confirmed non-alcoholic fatty liver disease were treated with 200mg/day of
fenofibrate for 48 weeks. A clinical and biochemical follow-up was done every 3 months. A …